Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb541 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation and Dose Expansion of XmAb541 and XmAb808 | EXPERIMENTAL | - |
| Dose escalation and Dose Expansion of XmAb541 | EXPERIMENTAL | Intravenous or Subcutaneous administration |
| Name | Type | Description |
|---|---|---|
| XmAb541 | BIOLOGICAL | Monoclonal Bispecific Antibody |
| XmAb808 | BIOLOGICAL | Monoclonal Bispecific Antibody |
Inclusion Criteria: * Age ≥ 18 years. * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallopian tube or primary peritoneal origin * Adequate Eastern Cooperative Oncology Group performance ...
Top 20 of 59 competitors
XmAb541 is an investigational monoclonal antibody being developed for ovarian cancer. It is currently in Phase 1 clinical trials studying its safety and tolerability in advanced solid tumors, including ovarian cancer. The drug is not yet approved and remains in clinical development.
XmAb541 targets CLDN6, a protein found on the surface of certain tumor cells. By binding to CLDN6, the antibody is designed to direct an immune response against cancer cells expressing this protein. This mechanism is being evaluated in early-stage clinical trials for ovarian cancer.
XmAb541 is being developed by Xencor, Inc., a biopharmaceutical company traded on NASDAQ under the ticker XNCR. Xencor is conducting Phase 1 clinical trials to evaluate the safety and tolerability of XmAb541 in patients with advanced solid tumors.
XmAb541 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 trials are currently recruiting patients to assess the safety, tolerability, and preliminary activity of XmAb541 in advanced solid tumors.
XmAb541 is being studied in two Phase 1 trials. NCT06276491 evaluates XmAb541 alone in advanced solid tumors, including ovarian, endometrial, and germ cell tumors, with an enrollment of 282. NCT07593092 studies XmAb541 in combination with XmAb808 in ovarian cancer, enrolling 90 patients.
No, XmAb541 and XmAb808 are different investigational drugs. XmAb541 targets CLDN6 and is being studied alone or in combination with XmAb808. A Phase 1 trial, NCT07593092, is evaluating the combination of XmAb541 and XmAb808 in patients with ovarian cancer.